Melanoma vaccine shows promise
Prolonged, repeated vaccination can slow or stop disease progression in patients with advanced melanoma, say South Australian researchers.
Developed at the University of Adelaide, the Vaccinia Melanoma Cell Lysate (VMCL) vaccine was recently trialed in 54 melanoma patients, 48 of whom had stage IV disease and six with advanced stage III disease.
Strong, durable clinical responses with survival of at least two years occurred in around 30% of patients. Complete responses were recorded in 17% of cases and five-year survival was 15